Hepatic Encephalopathy: Management

Pathophysiology (Brief)

Fig. 94.1 - Sleisenger and Fordtran's Gastrointestinal and Liver Disease

Classification

Type by Underlying Disease

Severity: West Haven Criteria + SONIC

Precipitating Factors (ALWAYS identify and treat)

• GI bleeding (most common)
• Infection (including SBP - perform paracentesis if ascites present)
• Electrolyte abnormalities: hypokalemia, alkalosis (from diuretics or diarrhea)
• Azotemia / dehydration
• High protein intake
• Constipation
• Medications: opioids, sedative-hypnotics, benzodiazepines
• TIPS placement or surgical portosystemic shunts
• Progressive hepatocellular dysfunction
• Lactulose non-compliance

Acute Episode Management (Overt HE)

Step 1 - Supportive Care

• Secure airway if Grade 3-4 (aspiration risk); ICU for Grade 3-4
• Correct electrolytes (especially K⁺, Na⁺, Mg²⁺)
• Monitor blood glucose; treat hypoglycemia
• Stop offending medications (opioids, benzodiazepines, diuretics in acute setting)
• Rule out structural causes if focal deficits present (head CT)

Step 2 - Identify and treat precipitant

• Blood cultures, urinalysis, diagnostic paracentesis (if ascites present)
• Treat infection aggressively; treat GI bleeding; correct coagulopathy

Step 3 - Reduce Ammonia

• Mechanism: non-absorbable disaccharide - acidifies colon, traps NH₄⁺, cathartic effect, reduces urease-producing bacteria
• Dose: 15-45 mL PO bid-qid titrated to 2-3 soft stools per day (Goldman-Cecil) / 3-5 soft stools/day (Washington Manual)
• Acute phase: 30 mL every 1-2 hours initially, then taper as bowel movements occur
• If oral not tolerated: Lactulose enema (300 mL lactulose + 700 mL distilled water)
• Avoid if ileus or bowel obstruction
• Complications: hypovolemia, hypernatremia (monitor closely)

• Mechanism: minimally absorbed broad-spectrum oral antibiotic; reduces intestinal ammonia-producing bacteria
• Dose: 550 mg PO twice daily (evidence-based dose) or 400 mg PO every 8 hours
• Adding rifaximin to lactulose: complete reversal of HE 76% vs. 50.8% with lactulose alone; decreased mortality 23.1% vs. 49.1%
• Add when no improvement in first 24 hours of lactulose alone
• Mulholland & Greenfield's Surgery, p. 2893

• 4350-electrolyte solution: 4 L orally or via NG tube over 4 hours
• Goldman-Cecil notes this may lead to more rapid clinical response than lactulose alone - an emerging option for acute episodes

Pharmacotherapy Summary

Secondary Prophylaxis (Prevention of Recurrence)

• Lactulose (primary) - titrated to 2-3 soft stools/day
• Add rifaximin 550 mg bid in patients with recurrent episodes (significantly reduces risk of recurrence and hospitalization in RCT)
• Can consider discontinuing only if precipitating factor is well controlled AND liver function/nutrition has improved
• Goldman-Cecil Medicine; Mulholland & Greenfield's Surgery

Dietary Considerations

• Do NOT restrict protein - protein restriction is harmful and not recommended chronically
• Target adequate protein intake (~1.2-1.5 g/kg/day)
• Switch from animal to vegetable source protein - may reduce ammonia generation in recurrent/persistent HE
• Small frequent meals; avoid prolonged fasting
• Late evening snack recommended (reduces catabolic state)

Management of Covert/Minimal HE

• Diagnosis: neuropsychological testing (abnormal in otherwise clinically normal patient)
• Treatment approach is still evolving
• Lactulose reduces progression to overt HE
• Rifaximin improves quality of life and driving performance in studies
• Probiotics have shown some benefit in trials

Special Situations

• Occurs in 10-50% post-TIPS
• Management: shunt reduction or occlusion may be required in refractory cases
• Rifaximin + lactulose as maintenance

• More likely to develop raised ICP and cerebral edema
• Osmotic therapy (mannitol 0.5-1 g/kg IV), head elevation
• Ammonia >150-200 µmol/L associated with cerebral herniation risk
• ICU management; consider liver transplant evaluation urgently

• Pre-TIPS lactulose/rifaximin may reduce post-TIPS HE incidence

Liver Transplantation

• Definitive treatment; generally reverses HE completely
• Refer for evaluation when HE occurs in context of decompensated cirrhosis
• Evaluate with Child-Pugh score ≥7 or MELD score ≥15
• Development of overt HE is a poor prognostic indicator: 1-year survival 20-42%, 3-year survival 15-23% without transplant

Diagnostic Pearls

• Ammonia level is neither sensitive nor specific - do not use to diagnose or grade HE
• EEG: slow, high-amplitude, triphasic waves (characteristic but non-specific)
• Asterixis (flapping tremor) present in Grades I-III (not Grade IV - coma)
• Always exclude: hypoglycemia, hyponatremia, intracranial hemorrhage, drug intoxication

Recent Evidence (2024-2026)

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Chapter 94
• Goldman-Cecil Medicine International Edition, Chapter 139
• Washington Manual of Medical Therapeutics, Chapter (Hepatology)
• Mulholland & Greenfield's Surgery, Chapter (Liver Transplantation)
• Rosen's Emergency Medicine, Chapter 13
• Symptom to Diagnosis: An Evidence-Based Guide, 4th Edition
• ACG Clinical Guideline (2026), PMID 41773757